Profile image
Story Views

Last Hour:
Last 24 Hours:

COPD Drugs Market 2016 Trend, Analysis and Overview

Wednesday, November 16, 2016 3:53
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Publisher’s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

For more information about this report:

Covered in this report 
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Publisher considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class: 
- Bronchodilators
- Phosphodiesterase-4 (PDE-4) inhibitors
- Steroids
- Combination therapies

Publisher’s report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- AstraZeneca
- Boehringer Ingelheim
- Merck
- Novartis


Request Sample Copy at   


Other prominent vendors 
- Ache Laboratorios Farmaceuticos 
- Almirall
- Aquinox Pharmaceuticals
- Ario Pharma
- BioMarck Pharmaceuticals
- Gilead Sciences
- Mereo BioPharma Group
- Mylan
- Orion
- Pearl Therapeutics
- Prosonix
- Teva Pharmaceutical Industry
- Theravance Biopharma
- Theron Pharmaceuticals
- Verona Pharma
- Xention
- ZAI Lab 

Market driver 
- Increase in environmental pollution
- For a full, detailed list, view our report 

Market challenge 
- Low diagnosis rate
- For a full, detailed list, view our report 

Market trend 
- Increased focus on combination therapies
- For a full, detailed list, view our report 


Inquire for Report at  


Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.